Evidence map›Paper›PMID 25122689›Full record

ArticleStem cells translational medicine2014

Different culture conditions modulate the immunological properties of adipose stem cells.

Mimmi Patrikoski, Jyrki Sivula, Heini Huhtala, Mika Helminen, Fanny Salo, Bettina Mannerström, Susanna Miettinen

Abstract read
In one paragraph

Article in Stem cells translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Is there a place for cellular therapy in depression?World journal of psychiatry · 2021
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mimmi PatrikoskiAdult Stem Cell Group, Institute of Biosciences and Medical Technology (BioMediTech), and School of Health Sciences, University of Tampere, Tampere, Finland; Science Center, Tampere University Hospital, Tampere, Finland mimmi.patrikoski@uta.fi.
Jyrki SivulaAdult Stem Cell Group, Institute of Biosciences and Medical Technology (BioMediTech), and School of Health Sciences, University of Tampere, Tampere, Finland; Science Center, Tampere University Hospital, Tampere, Finland.
Heini HuhtalaAdult Stem Cell Group, Institute of Biosciences and Medical Technology (BioMediTech), and School of Health Sciences, University of Tampere, Tampere, Finland; Science Center, Tampere University Hospital, Tampere, Finland.
Mika HelminenAdult Stem Cell Group, Institute of Biosciences and Medical Technology (BioMediTech), and School of Health Sciences, University of Tampere, Tampere, Finland; Science Center, Tampere University Hospital, Tampere, Finland.
Fanny SaloAdult Stem Cell Group, Institute of Biosciences and Medical Technology (BioMediTech), and School of Health Sciences, University of Tampere, Tampere, Finland; Science Center, Tampere University Hospital, Tampere, Finland.
Bettina MannerströmAdult Stem Cell Group, Institute of Biosciences and Medical Technology (BioMediTech), and School of Health Sciences, University of Tampere, Tampere, Finland; Science Center, Tampere University Hospital, Tampere, Finland.
Susanna MiettinenAdult Stem Cell Group, Institute of Biosciences and Medical Technology (BioMediTech), and School of Health Sciences, University of Tampere, Tampere, Finland; Science Center, Tampere University Hospital, Tampere, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential of human adipose stem cells (ASCs) for regenerative medicine has received recognition owing to their ease of isolation and their multilineage differentiation capacity. Additionally, low immunogenicity and immunosuppressive properties make them a relevant cell source when considering immunomodulation therapies and allogeneic stem cell treatments. In the current study, immunogenicity and immunosuppression of ASCs were determined through mixed lymphocyte reactions. The immunogenic response was analyzed after cell isolation and expansion in fetal bovine serum (FBS), human serum (HS)-supplemented medium, and xeno-free and serum-free (XF/SF) conditions. Additionally, the immunophenotype and the secretion of CXC chemokine ligand 8 (CXCL8), CXCL9, CXCL10, C-C chemokine ligand 2 (CCL2), CCL5, interleukin 2 (IL-2), IL-4, IL-6, IL-10, IL-17A, tumor necrosis factor-α, interferon-γ, transforming growth factor-β1, indoleamine 2,3-deoxygenase, Galectin-1, and Galectin-3 were analyzed. The results showed that ASCs were weakly immunogenic when expanded in any of the three conditions. The significantly strongest suppression was observed with cells expanded in FBS conditions, whereas higher ASC numbers were required to display suppression in HS or XF/SF conditions. In addition, statistically significant differences in protein secretion were observed between direct versus indirect cocultures and between different culture conditions. The characteristic immunophenotype of ASCs was maintained in all conditions. However, in XF/SF conditions, a significantly lower expression of CD54 (intercellular adhesion molecule 1) and a higher expression of CD45 (lymphocyte common antigen) was observed at a low passage number. Although culture conditions have an effect on the immunogenicity, immunosuppression, and protein secretion profile of ASCs, our findings demonstrated that ASCs have low immunogenicity and promising immunosuppressive potential whether cultured in FBS, HS, or XF/SF conditions.

Indexed as

AdipocytesAdultCell Culture TechniquesCells, CulturedFemaleFlow CytometryHumansLymphocyte Culture Test, MixedStem CellsAdipose stem cellsCellular therapyCytokinesImmunogenicityImmunosuppressionSerum-free

Identifiers

PMID25122689
PMCPMC4181391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.